The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
AACR 2017 | Poster 2161/12 – Pharmacological downregulation of BFL-1 by CPI203 overcomes ABT-199 resistance in Double Hit Lymphoma
On Monday 3rd April during this year’s American Association for Cancer Research (AACR) annual meeting, a poster (2161 / 12) by Anna Esteve-Arenys, from IDIBAPS, Barcelona, Spain, et al. titled “Pharmacological downregulation of BFL-1 by the BET bromodomain inhibitor CPI203 overcomes ABT-199 resistance in MYC+/BCL2+ double hit lymphoma” was presented.
The group aimed to: assess the anti-tumor effect of ABT-199 (venetoclax) in Double Hit Lymphoma (DHL) cell lines, explore the role of bromodomain inhibition in overcoming resistance to ABT-199, and to evaluate the combination of ABT-199 and CPI203 (BET inhibitor) in in vitro and in vivo models of DHL.
Key Highlights:
- ABT-199, in a dose and time-dependent manner, decreased cell proliferation
- A significant decrease in ABT-199 efficacy was reported at 96h in DHL cell lines (cell viability increased from 53–78% from 24 to 96hrs after 100nM treatment)
- Prolonged exposure of ABT-199 induced BFL-1 overexpression in DHL cell lines
- BFL-1 upregulation was associated with resistance to ABT-199 in DHL cell lines
- CPI203 decreased BFL-1 and increased BIM expression in DHL cell lines and primary samples
- ABT-199 combined with CPI203 demonstrated synergistic pro-apoptotic activity
- In SCID mice subcutaneously injected with Oci-Ly8 cells, those treated with ABT-199 and CPI203 displayed a significantly larger reduction in tumor growth and size versus those in the control group (P < 0.001)
The poster was concluded by stating that expression and persistence of BFL-1 governs the sensitivity of DHL cells and xenograft models to ABT-199. The group found that BF-L1 expression can be reduced in vitro and in vivo by CPI203 allowing apoptosis to be induced by ABT-199. The group stress that this novel combination should be evaluated clinically in patients with aggressive DHL.
References